FDA Opioid Action Plan Means More Advisory Committees And A New Look At REMS, PMRs
This article was originally published in RPM Report
Executive Summary
FDA announced February 4 that it is undergoing a “far-reaching action plan” to assess its approach to opioid medications in a bid to resolve one of the final obstacles blocking confirmation of Robert Califf as FDA Commissioner.
You may also be interested in...
Opana IR Pediatric Labeling Supplement Faces US FDA Panel Review
Endo seeks to add findings from two open-label pediatric studies to labeling for its immediate-release opioid analgesic but is not seeking a pediatric use indication; advisory committee also will consider whether something more than routine pediatric safety monitoring is needed for Purdue’s OxyContin, which added a pediatric indication in 2015.
Purdue Butrans Pediatric Study Added To Label – Sort Of
US FDA has updated the label for Purdue’s opioid pain therapy Butrans to note the existence of a pediatric study for the buprenorphine formulation. After consulting with its advisory committee, FDA didn’t include any further information.
OxyContin Repeat? US FDA Seeks To Avoid Fallout Over Butrans Pediatric Data
Advisory committees will discuss whether data from a 41-patient study should be added to Pediatric Use section of labeling for Purdue's buprenorphine product; agency's decision to convene expert panel even though a pediatric indication is not being considered grew out of criticism generated by approval of OxyContin for adolescents.